Regulatory Update

| 01 August 2011 |  By 

The Food and Drug Administration (FDA) understands the potential importance of companion diagnostics in the future of personalized medicine. Although a few companion diagnostics have been approved, there are many more in development. Therapeutics that depend upon the use of in vitro diagnostic (IVD) tests have unique regulatory requirements. FDA released a draft guidance to assist sponsors in the development of IVD companion diagnostics.


© 2022 Regulatory Affairs Professionals Society.

Discover more of what matters to you

No taxonomy